Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer
about
Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implicationsAnti-endothelin drugs in solid tumors.Phase 1/2 study of atrasentan combined with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer.Role of the endothelin axis and its antagonists in the treatment of cancerPreliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysisRandomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosisEndothelin inhibits cholangiocarcinoma growth by a decrease in the vascular endothelial growth factor expressionStromal endothelin B receptor-deficiency inhibits breast cancer growth and metastasis.Therapeutic potential of endothelin receptor modulators: lessons from human clinical trials.Novel targets for VEGF-independent anti-angiogenic drugs.Potential of targeted drug delivery system for the treatment of bone metastasis.Atrasentan (ABT-627) enhances perfusion and reduces hypoxia in a human tumor xenograft model.Endothelin causes transactivation of the EGFR and HER2 in non-small cell lung cancer cells.
P2860
Q29006772-D8F30863-FBD0-4EE8-9D40-162991C93621Q30239808-FF7C2E18-CA43-41B2-86B4-2EFFD065FBC1Q34021011-6A8011A7-68F8-4484-9B29-F86357579263Q34300629-B2366063-2B5F-44E4-88B1-CB1705E05CDCQ34919570-B35542E0-11C5-488F-9356-8E80502A10E5Q35722493-A95FB45A-221B-4945-90C6-4A81F0AF9532Q36951721-8653ACB2-51BB-46A4-8433-2A5F1039DC8EQ37174006-9812A140-435A-4EDE-B269-C9C840418179Q37253350-1B7D754C-39C9-4604-9DC7-0343A2475135Q37310022-7CF37688-3541-4947-9218-C3C3E6111D26Q37573815-5ECF9555-BC4D-4223-97E7-7B930E2936B7Q37984612-3A7BC63C-51A8-42FC-BE1F-AD3979C2EF34Q38212708-BDE16B6A-0413-45D5-8721-C92D683BF89BQ41484298-DE8E02DD-4D9A-4D3D-A603-D9A1189B3019Q46424042-B260ACE2-AEE5-4672-8642-B9765C8A391A
P2860
Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Phase I/II study of atrasentan ...... ced non-small cell lung cancer
@ast
Phase I/II study of atrasentan ...... ced non-small cell lung cancer
@en
Phase I/II study of atrasentan ...... ced non-small cell lung cancer
@nl
type
label
Phase I/II study of atrasentan ...... ced non-small cell lung cancer
@ast
Phase I/II study of atrasentan ...... ced non-small cell lung cancer
@en
Phase I/II study of atrasentan ...... ced non-small cell lung cancer
@nl
prefLabel
Phase I/II study of atrasentan ...... ced non-small cell lung cancer
@ast
Phase I/II study of atrasentan ...... ced non-small cell lung cancer
@en
Phase I/II study of atrasentan ...... ced non-small cell lung cancer
@nl
P2093
P1476
Phase I/II study of atrasentan ...... ced non-small cell lung cancer
@en
P2093
Alberto A Chiappori
Anthony M Neuger
Barbara Padilla
Charles Williams
Daniel M Sullivan
David Boulware
Eric Haura
Francisco A Rodriguez
George Simon
Gerold Bepler
P304
P356
10.1158/1078-0432.CCR-07-1508
P407
P577
2008-03-01T00:00:00Z